A single dose ascending and repeated dose, randomised, double-blind, placebo-controlled study to assess the safety, pharmacokinetics and pharmacodynamics of CSL324 in healthy, adult male and female subjects.

Trial Profile

A single dose ascending and repeated dose, randomised, double-blind, placebo-controlled study to assess the safety, pharmacokinetics and pharmacodynamics of CSL324 in healthy, adult male and female subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs CSL 324 (Primary) ; Cantharidin; Filgrastim
  • Indications Immunological disorders; Inflammation; Rheumatic disorders
  • Focus Adverse reactions; First in man
  • Sponsors CSL
  • Most Recent Events

    • 17 Jul 2017 Planned number of patients changed from 56 to 58.
    • 12 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 10 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top